Fig 4. Ingenuity pathway analysis after JM6 treatment.

(A) JM6 treatment significantly affects genes in pathways linked to depression, including axonal guidance, CREB and Huntington’s disease signaling. (B) The top immune response pathways affected by JM6 treatment are also linked to depression, including CXCR, IL-4 and NF-κB activation by virus signaling. Threshold indicates minimum significance level [–log (p-value) from Fisher’s exact test]. Ratio refers to the number of molecules from the dataset that map to the pathway listed, divided by the total number of molecules that define the canonical pathway from within the IPA knowledgebase. (C) JM6 influences the synaptic long-term depression pathway by upregulating AMPA receptor signaling.